Sionna Therapeutics Reports $310M Cash Runway Into 2028, Pipeline Trials On Track
Summary
Sionna Therapeutics reported its Q4 and full-year 2025 financial results, showing increased R&D and G&A expenses, leading to a higher net loss of $75.3 million for the full year. Crucially, the company maintained a strong cash position of approximately $310.3 million, which is expected to fund operations into 2028. This extended cash runway significantly de-risks near-term financing concerns for the clinical-stage biopharmaceutical company. Additionally, Sionna confirmed that its PreciSION CF Phase 2a trial for SION-719 and Phase 1 dual combination trial for SION-451 are both on track, with topline data anticipated in mid-2026, maintaining development momentum.
At the time of this announcement, SION was trading at $36.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $7.26 to $45.00. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.